Meta-Analysis
Copyright ©The Author(s) 2020.
World J Gastroenterol. May 14, 2020; 26(18): 2247-2267
Published online May 14, 2020. doi: 10.3748/wjg.v26.i18.2247
Table 1 Characteristics of articles using computed tomography imaging to diagnose esophageal varices
Ref.Study designTotal patientsMean age (yr)Male (%)Etiology (%)Child-Pugh class (%)CT scannerInterval between CT and endoscopyPresence of EV
TPFPFNTN
Cansu et al[33], 2014Prospective5056.854HBV (40.0); HCV (30.0); Biliary (6.0); HBV + HCV (4.0); Alcohol (4.0%); Others (16.0)A (52.0); B (36.0); C (12.0)16-sliceWithin 4 wk332015
Prospective4256.269HBV (45.2); HCV (23.8); Alcohol (4.8); HBV + HCV (2.4); Biliary (2.4); Others (21.4)A (38.1); B (31.0); C (31.0)16-sliceWithin 4 wk25386
Deng et al[34], 2016Retrospective5255.463.5Alcohol (30.8); HBV (25.0); HBV + Alcohol (9.6); HCV (3.8); HBV + HCV (1.9); Others (28.9)A (49.0); B (39.2); C (11.8)NRNR43225
Desso-uky et al[35], 2013Prospective13758.753.3HCV (67.9); HBV (19.7); HBV + HCV (10.2); Steatohepatitis (2.2)A (55); B (31); C (14)16-sliceWithin 24 h891146
Elalfy et al[36], 2016Retrospective12456.552HCV (100)A (62.9); B (37.1)16-sliceNR704446
Elkammash et al[37], 2015NR11251.468.8HBV (46); HCV (44); Schisto-somiasis (10)NR64-sliceWithin 2 wk970213
990013
Jiang et al[38], 2015NR895764HBV (71.9); Alcohol (11.2); HCV (7.9); Biliary (5.6); Drug (1.1); Unknown (2.3)NR64-sliceNR583820
Kim et al[40], 2020Retrospective1045974HBV (72.1); HCV (12.5); Alcohol (6.7); Others (8.7)A (41.3); B (30.8); C (27.9)16 or 64-sliceWithin 4 wk1809811
16991911
17215165
Kim et al[41], 2007Prospective9054.872.2HBV (73.3); HCV (21.1); Alcohol (2.2); Others (3.3)A (81.1); B (18.9)16-sliceWithin 4 h5015322
4712625
4613724
468729
Kim et al[42], 2007Retrospective6756.258.2HCV (35.8); HBV (22.4); Alcohol (22.4); HBV + HCV (9.0); Others (10.4)A (23.9); B (37.3); C (38.8)NRWithin 4 wk2961319
2731522
Lipp et al[43], 2011Retrospective29955.264.9NRNR4 or 16 or 64-sliceWithin 12 wk5424752
41173077
Moftah et al[44], 2014NR5456.874.1NRNR8-sliceNR48024
Perri et al[45], 2008Retrospective101NR63.4Viral (21.8); Alcohol (18.8); Biliary (17.8); NASH (14.9); Others (26.7)A (44.6); B (39.6); C (15.8)4-slice or higher2 d17310612
68121110
Wu et al[46], 2009Prospective5057.760HBV (76); Autoimmune (2); Others (22)A (26.0); B (62.0); C (12.0)16-sliceWithin 4 wk39326
40514
Yu et al[47], 2011Retrospective10955.955HCV (46.8); Alcohol (17.4); HBV (6.4); Others (29.4)NR16 or 64-sliceNR50101237
50121235
49241323
47171530
Zhao et al[48], 2016Retrospective14352.3967.1HBV (70.6); Alcohol (11.2); Autoimmune (4.9); HCV (3.5); Biliary (3.5); Others (6.3)A (37.8); B (33.6); C (28.7)64-slice3.4 d2113127
2
Zhu et al[49], 2009Retrospective12745.275.6HBV (74.8); Alcohol (10.2); HCV (4.7); Others (10.2)A (37.8); B (37.0); C (25.2)4-sliceWithin 4 wk72151426
67111930
Table 2 Characteristics of articles using computed tomography imaging to predict HREV
Ref.Study designTotal patientsMean age (yr)Male (%)Etiology (%)Child-Pugh class (%)CT scannerCut-off value (mm)Interval between CT and endoscopyPresence of HREV
TPFPFNTN
Deng et al[34], 2016Retrospective5255.464Alcohol (30.8); HBV (25.0); HBV + Alcohol (9.6); HCV (3.8); HBV + HCV (1.9); Others (28.9)A (49.0); B (39.2); C (11.8)NREVD 3.9NR35449
Dessouky et al[35], 2013Prospective13758.753HCV (67.9); HBV (19.7); HBV + HCV (10.2); Steato-hepatitis (2.2)A (55); B (31); C (14)16-sliceEVD 3.0Within 24 h380099
Elalfy et al[36], 2016Retrospective12456.552HCV (100)A (62.9); B (37.1)16-slicePVD 12.5NR33491329
Kim et al[39], 2008Retrospective1106174HBV (60.9); HCV (29.1) Alcohol (6.4); HBV + HCV (1.8); Others (1.8)A (63.6); B (26.4); C (10.0)16-sliceEVD 2.08.2 d112315961
11321959
115151761
Kim et al[40], 2020Retrospective1045974HBV (72.1); HCV (12.5); Alcohol (6.7); Others (8.7)A (41.3); B (30.8); C (27.9)16 or 64-sliceEVD 2.0Within 4 wk343370
3610163
324569
Kim et al[41], 2007Prospective9054.872HBV (73.3); HCV (21.1); Alcohol (2.2); Others (3.3)A (81.1); B (18.9)16-sliceGrade 2 and Grade 33Within 4 h2811249
285255
279351
272358
Kim et al[42], 2007Retrospective6756.258HCV (35.8); HBV (22.4); Alcohol (22.4); HBV + HCV (9.0); Others (10.4)A (23.9); B (37.3); C (38.8)NREVD 3.0Within 4 wk119146
119146
Lipp et al[43], 2011Retrospective29955.265NRNR4 or 16 or 64-sliceEVD 4.0Within 12 wk18111296
12422127
Perri et al[45], 2008Prospective101NR63Viral (21.8); Alcohol (18.8); Biliary (17.8); NASH (14.9); Others (26.7)A (44.6); B (39.6); C (15.8)4-slice or higherEVD 5.02 d22351855
2781452
Yu et al[47], 2011Retrospective10955.955HCV (46.8); Alcohol (17.4); HBV (6.4); Others (29.4)NR16 or 64-sliceEVD 2.0NR2524159
2518165
2341342
2317366
Table 3 Overview of results of meta-analysis
GroupLSM for presence of EVLSM for presence of HREVCT for presence of EVCT for presence of HREVMRI for presence of EVMRI for presence of HREV
Diagnostic threshold
Spearman correlation coefficient0.360.21-0.20.120.270.57
P value0.190.50.270.580.560.11
SROC
AUSROC (95%CI)0.86 (0.83-0.89)0.85 (0.81-0.88)0.91 (0.88-0.93)0.94 (0.91-0.96)0.86 (0.83-0.89)0.83 (0.79-0.86)
I297.43%97.13%97.17%98.30%86.41%91.64%
P value< 0.01< 0.01< 0.01< 0.01< 0.01< 0.01
Sensitivity
Summary sensitivity (95%CI)0.84 (0.78-0.89)0.81 (0.75-0.86)0.91 (0.87-0.94)0.88 (0.82-0.92)0.81 (0.76-0.86)0.80 (0.72-0.86)
I282.63%70.93%88.46%87.06%33.57%67.03%
P value< 0.01< 0.01< 0.01< 0.010.17< 0.01
Specificity
Summary specificity (95%CI)0.71 (0.60-0.80)0.73 (0.66-0.80)0.75 (0.68-0.82)0.87 (0.81-0.92)0.82 (0.70-0.89)0.72 (0.62-0.80)
I286.56%91.65%80.58%93.26%74.53%83.17%
P value< 0.01< 0.01< 0.01< 0.01< 0.01< 0.01
PLR
Summary PLR (95%CI)2.91 (2.08-4.06)3.04 (2.38-3.89)3.67 (2.73-4.94)6.90 (4.54-10.49)4.44 (2.74-7.21)2.83 (2.11-3.80)
I282.66%85.63%83.81%91.04%31.66%51.94%
P value< 0.01< 0.01< 0.01< 0.010.01< 0.01
NLR
Summary NLR (95%CI)0.22 (0.16-0.30)0.26 (0.19-0.34)0.12 (0.08-0.18)0.14 (0.09-0.21)0.23 (0.18-0.28)0.28 (0.21-0.38)
I279.49%68.30%88.94%91.10%<0.01%43.01%
P value< 0.01< 0.01< 0.01< 0.010.530.08
Summary DOR (95%CI)13.01 (7.83-21.64)11.93 (7.89-18.03)30.98 (16.02-59.91)49.99 (25.38-98.43)19.58 (11.39-33.66)10.00 (6.63-15.09)